Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,356.20 93.64 0.58%
S&P 500 1,848.40 5.42 0.29%
NASDAQ 4,056.15 21.98 0.54%
Ticker Volume Price Price Delta
STOXX 50 3,125.30 33.78 1.09%
FTSE 100 6,574.15 32.54 0.50%
DAX 9,272.38 98.67 1.08%
Ticker Volume Price Price Delta
NIKKEI 14,417.68 420.87 3.01%
TOPIX 1,166.55 30.46 2.68%
HANG SENG 22,696.01 24.75 0.11%

Updated Estimates, Stock Movements, and Regulatory Approvals - Research Report on Quest Diagnostics, Zimmer Holdings, Pacira



Updated Estimates, Stock Movements, and Regulatory Approvals - Research Report
  on Quest Diagnostics, Zimmer Holdings, Pacira Pharmaceuticals, Geron, and
                          Oculus Innovative Sciences

Editor Note: For more information about this release, please scroll to bottom.

PR Newswire

NEW YORK, December 18, 2013

NEW YORK, December 18, 2013 /PRNewswire/ --

Today, Analysts' Corner announced new research reports highlighting Quest
Diagnostics Inc. (NYSE: DGX), Zimmer Holdings, Inc. (NYSE: ZMH), Pacira
Pharmaceuticals Inc. (NASDAQ: PCRX), Geron Corporation (NASDAQ: GERN), and
Oculus Innovative Sciences, Inc. (NASDAQ: OCLS). Today's readers may access
these reports free of charge - including full price targets, industry analysis
and analyst ratings - via the links below.

Quest Diagnostics Inc. Research Report

On December 12, 2013, Quest Diagnostics Inc. (Quest Diagnostics) updated its
estimates for full-year 2013 revenues and adjusted diluted earnings per share,
on a continuing operations basis and before special items. According to the
Company, it previously updated its full-year 2013 guidance on October 17,
2013. According to the new update, the Company's expectations for the
full-year 2013 indicate the revenues to decline by approximately 3.5% YoY and
adjusted earnings per diluted share to be between $3.90 and $3.95. Quest
Diagnostics intends to provide guidance for its full-year 2014 in conjunction
with its report of Q4 2013 results in January 2014, as is customary for the
Company. The Full Research Report on Quest Diagnostics Inc. - including full
detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:

http://www.analystscorner.com/r/full_research_report/05ba_DGX

--

Zimmer Holdings, Inc. Research Report

On December 13, 2013 Zimmer Holdings, Inc.'s (Zimmer Holdings) stock rose
0.57%, ending the day at $90.51. Over the previous three trading sessions,
shares of Zimmer Holdings declined 1.49%, compared to the Dow Jones industrial
average which declined 1.36% during the same period. The Full Research Report
on Zimmer Holdings, Inc. - including full detailed breakdown, analyst ratings
and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/9db9_ZMH

--

Pacira Pharmaceuticals Inc. Research Report

On December 13, 2013, Pacira Pharmaceuticals Inc. (Pacira Pharmaceuticals)
stock rose 1.81%, ending the day at $50.07. Over the previous three trading
sessions, shares of Pacira Pharmaceuticals declined 1.40%, compared to the
Nasdaq Composite which declined 1.47% during the same period. The Full
Research Report on Pacira Pharmaceuticals Inc. - including full detailed
breakdown, analyst ratings and price targets - is available to download free
of charge at:

http://www.analystscorner.com/r/full_research_report/c0aa_PCRX

--

Geron Corporation Research Report

On December 13, 2013, Geron Corporation's (Geron) stock declined 0.21%, ending
the day at $4.77.  Over the previous three trading sessions, shares of Geron
declined 7.38%, compared to the Nasdaq Composite which declined 1.47% during
the same period. The Full Research Report on Geron Corporation - including
full detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:

http://www.analystscorner.com/r/full_research_report/1ca9_GERN

--

Oculus Innovative Sciences, Inc. Research Report

On December 12, 2013, Oculus Innovative Sciences, Inc. (Oculus Innovative
Sciences) announced a regulatory approval in Mexico for the Company's new
Microcyn-based scar management hydrogel, under the brand name Epicyn. Bruce
Thornton, Executive Vice President of Oculus Innovative Sciences, said, "From
a corporate perspective, this is just the first of many opportunities for our
new scar management hydrogel formulation outside the United States. In
addition to the approval by the Mexican Ministry of Health, our Latin American
partner, More Pharma, in parallel with the introduction of the new Epicyn™
Scar Hydrogel in the Mexican dermatology market, intends to move forward to
secure regulatory approvals, and subsequent product launches, in additional
Latin American countries as well. We are exceedingly proud of our teams in
both Mexico and the United States for working in tandem to secure respective
regulatory approvals." The Company further reported that it previously
announced FDA 510(k) regulatory clearance for the Microcyn Scar Management
HydroGel. The Full Research Report on Oculus Innovative Sciences, Inc. -
including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/a3ee_OCLS

----

EDITOR NOTES:

 1. This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
 2. Information in this release is fact checked and produced on a best efforts
    basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are
    only human and are prone to make mistakes. If you notice any errors or
    omissions, please notify us below.
 3. This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
 4. If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
 5. For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
 6. Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider represented by Ananya Ghosh, CFA, has
only reviewed the information provided by Equity News Network in this article
or report according to the Procedures outlined by Equity News Network. Equity
News Network is not entitled to veto or interfere in the application of such
procedures by the outsourced provider to the articles, documents or reports,
as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
Institute.

AnalystsCorner.com

SOURCE Analysts' Corner

Contact: Joe Thomas, CONTACT PHONE: +1-310-496-8071 (North America)
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement